

Validation of Breast Cancer Microarray Analysis Using Molecular Biology Techniques

Thesis

*Submitted for Partial Fulfillment for the Requirement of
Master Degree in Basic Science (Medical Biochemistry)*

Presented by

Amal Said Mohammed Darweesh

Demonstrator of medical Biochemistry and Molecular Biology
Faculty of Medicine – Ain Shams University

Under Supervision of

Professor/ Samar Kamal Kassim

Professor of Medical Biochemistry and Molecular Biology
Faculty of Medicine - Ain Shams University

Doctor/ Mohamed El-Sayed El-Shinawi

Assistant Professor of General Surgery
Faculty of Medicine - Ain Shams University

Doctor/ Manal Louis Louka

Lecturer of Medical Biochemistry
and Molecular Biology
Faculty of Medicine - Ain Shams University

**Faculty of Medicine
Ain Shams University
2013**

LIST OF CONTENTS

Title	Page
♦ List of Tables	I
♦ List of Figures	II
♦ List of Abbreviations	III
♦ Introduction	1
♦ Aim of the Work	3
♦ Review of the Literature:	
❖ Breast Cancer	4
■ Epidemiology of Breast Cancer	4
■ Risk factors of Breast cancer	6
1- Age	6
2-Sex	6
3-Hormones & Pregnancy	7
4-Previous Breast Neoplasm	8
5-Enviromental exposures	8
6-Breast density	8
7-Family history & Genetics	8
■ Molecular Biology of Breast Cancer	12
■ Histopathological Classification of Breast Cancer	15
■ The Biological Classification Of Breast Cancer	22
■ Staging of Breast Cancer	23

LIST OF CONTENTS (CONT.)

Title	Page
❖ Microarray	24
■ Types of microarrays include	24
■ DNA microarrays	24
❖ Human growth factor receptor bound protein 7 (Grb7)	31
■ Structure Function of Grb7	31
■ Role of Grb7 in cell migration	35
○ Interaction of Grb7 with EGF	36
○ Interaction of Grb7 with FAK	38
○ Association of Grb7 with Phosphoinositides ...	41
❖ Homo Sapiens Tweety Family	44
♦ Patients and Methods	46
♦ Results	61
♦ Discussion	73
♦ Summary	81
♦ Conclusion	86
♦ References	87
♦ Arabic summary	--

LIST OF TABLES

Tab. No	Title	Page
Table (1):	Established and possible risk factors for breast cancer	11
Table (2):	Immunohistochemical characterization of molecular subtypes of breast cancer.....	22
Table (3):	Breast cancer stage grouping.....	23
Table (4):	Sequence of Grb7 primers	51
Table (5):	Sequence of TTYH1 primers.....	52
Table (6):	Sequence of GAPDH primers	52
Table (7):	The different breast cancer risk factors among the studied group	62
Table (8):	Grb7 expression among the studied groups.....	63
Table (9):	The relation between Grb7 expression and the different risk factors in the breast cancer group	67
Table (10):	The Relation Between Grb7 and the different clinicopathological parameters in the breast cancer group.....	69
Table (11):	The relation between Grb7 expression and the hormonal receptor status in the breast cancer group	70
Table (12):	The relation between Grb7 expression and the molecular subsets in the breast cancer group.....	71
Table (13):	Sensitivity and specificity, predictive values and accuracy of RT-PCR of Grb7 in breast cancer	72

LIST OF FIGURES

Fig. No	Title	Page
Figure (1):	The overall organization of Grb7 and its products	31
Figure (2):	The modular organization of Grb7 protein. Numbers indicate the residue number of the amino acids.....	32
Figure (3):	Grb7 as a mediator of several signalling pathways	34
Figure (4):	FAK structural features and interaction proteins	39
Figure (5):	Analytical gel electrophoresis for Grb7 in breast cancer tissue	63
Figure (6):	Analytical gel electrophoresis for Grb7 in normal breast tissue.....	64
Figure (7):	Analytical gel electrophoresis for GAPDH in breast tissue.....	65
Figure (8):	Analytical gel electrophoresis for TTYH1	66

LIST OF ABBREVIATIONS

Abbrev.	Full Term
Ajcc	American joint committee on cancer
Arg	Argenine
BPS	Between PH and SH2 domains
BRCA-1	Breast Related Cancer Antigen- 1
BRCA-2	Breast Related Cancer Antigen- 2
CDKIs	Cyclin dependant kinase inhibitors
CDKs	Cyclin dependant kinases
cDNA	Complementary Deoxyribonucleic Acid
CIS	Non-invasive carcinomas
CK :	Cytokeratins
cRNA	complementaryribonucleic Acid
DCIS	Ductal carcinoma in situ
DNA	Deoxyribonucleic Acid
EDTA	Ethylene diamine tetraacetic acid
EGRF	Epidermal growth factor receptor
EphB1	Ephrin type-B receptor
ER	Estrogen Receptors
ErbB1	Avian erythroblastosis oncogene B-1
ErbB2	Avian erythroblastosis oncogene B-2
ErbB3	Avian erythroblastosis oncogene B-3
ErbB4	Avian erythroblastosis oncogene B-4
ERK1/2	Extracellular signal-regulated kinase
FAK	Focal adhesion kinase
FN	Fibronectin

LIST OF ABBREVIATIONS (CONT.)

Abbrev.	Full Term
G0 phase ...	Gap zero phase of the cell cycle
GAPDH	Glyceraldehyde 3 phosphate dehydrogenase
GM	Region for Grb and Mig
Grb10	Human growth factor receptor bound protein 10
Grb14	Human growth factor receptor bound protein 14
Grb7	Human growth factor receptor bound protein 7
HER-2	Human Epidermal growth factor Receptor 2
IHC	Immunohistochemistry
JNK	c-Jun N-terminal kinase
kDa	kilodalton
KOR	Kappa opioid receptor
LCIS	Lobular carcinoma in situ
Lys	Lysine
M phase	Mitosis phase of the cell cycle
MAPKs	Mitogen-activated protein kinase
P16	Gene codes for a 16 kilodalton protein
P27	Gene codes for a 27 kilodalton protein
p38	Gene codes for a 38 kilodalton protein
P53	Gene codes for a 53 kilodalton protein
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
PH	Pleckstrin homology domain

LIST OF ABBREVIATIONS (CONT.)

Abbrev.	Full Term
Phe	Phenylalanine
PI3-K	Phosphatidylinositol 3-kinase
PR	Progesterone Receptors
pRb	Retinoblastoma protein
QC	Quality control
RA	Ras-associating domain
Ras	Rat sarcoma
RT-PCR	Reverse transcriptase - polymerase chain reaction
Rb	Retinoblastoma gene
RNA	Ribonucleic Acid
TBE	Trisma, Boric and EDTA
S phase	DNAsynthesis phase of the cell cycle
SH2	Src homology 2
SNP	Single nucleotide polymorphism
Src family ..	Sarcoma virus
STAT3	Signal transducer and activator of transcription-3
TTYH1	Tweety homologue 1
TTYH2	Tweety homologue 2
TTYH3	Tweety homologue 3
Tyr	Tyrosine

ACKNOWLEDGEMENT

First and foremost, thanks to **GOD**, to whom I relate any success in achieving work in my life

I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Samar Kamal Kassim**, Professor of Medical Biochemistry and molecular Biology, Faculty of Medicine, Ain Shams University It is a real pleasure to acknowledge her sincere encouragement, valuable guidance, constant advice and resourceful knowledge.


I would also like to thank **Dr. Mohamed El-Sayed El-Shinawi**, Assistant Professor of General Surgery, Faculty of Medicine, Ain Shams University for his great help and kind support.

I owe special gratitude to **Dr. Manal Louis Louka**, Lecturer of Medical Biochemistry and molecular Biology, Faculty of Medicine, Ain Shams University for her resourceful knowledge, close supervision and continuous advice.

This work was supported by Ain Shams Faculty of Medicine Grant's Office.



Amal Said Mohammed Darweesh



(قَالُوا سُبْحَانَكَ لَا عِلْمَ كُنَّا

إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ)

صدق الله العظيم

سورة البقرة آية (32)

Introduction

Breast cancer is a major health burden worldwide. It is the most common cause of cancer among females in both developed and developing countries. It is responsible for over 1 million of the estimated 10 million neoplasms diagnosed worldwide each year in both sexes (*Bray et al., 2004*).

Breast cancer is the second leading cause of cancer deaths in general after lung cancer and it is the most common cancer among women worldwide (*Laurance and Jeremy, 2006*).

In Egypt, breast cancer is the most common cancer among women, representing 18.9% of total cancer cases among the Egyptian National Cancer Institute (NCI) and represents 37.5% of all reported tumors in Egyptian females (*Salem et al., 2010*).

In the past several years, a new technology, called microarray, has attracted great interests among biologists. This is because traditional methods generally work on a gene in one experimental basis, which means that the throughput is very limited. This technology promises to monitor the whole genome on a single chip so that the researchers can have a better picture of the interactions among thousands of genes simultaneously. They are useful when one wants to survey a large number of genes quickly or when the sample to be studied is small.

A previously done microarray data on breast cancer by *Hana et al. (2009)* showed that members of the growth factor receptor family overexpression have been of considerable interest in tumorigenesis (e.g. Grb7). While, it also highlighted some genes to be related to breast cancer for the first time. Among these was the gene called TTYH1 which was found to be significantly under expressed in Breast cancer.

Growth factor receptor-bound protein-7 (Grb-7) is a member of the Grb-7/-10/-14 family. It has been implicated in important cellular and physiological functions such as signal transduction, cell motility and tumor progression (*Cariou et al., 2004*).

Tweety, belongs to a family which includes three members, designated as TTYH1 (Tweety homologue 1), TTYH2 and TTYH3. It recently identified Cl⁻ channels predicted to be modified by N-glycosylation (*Yaowu et al., 2008*).

Aim of the Work

The aim of this study is to validate the results obtained from the previous microarray data analysis with respect to the above mentioned genes (Grb-7 & TTYH1). Also, we will study the relation between their expression and the development of the disease. Moreover, their relation with the different bad prognostic indicators will also be addressed.

Breast Cancer

Breast cancer represents a serious health problem and is currently the most frequent malignancy in female population.

It is the most common cause of cancer related mortalities among women worldwide. The basic understanding of breast cancer initiation and progression is still incomplete.

In addition, there is a need to develop improved methods to stratify breast cancer patients into different risk groups more accurately than can be achieved with current clinicopathologic classification methods. Hence, low-risk patients can be spared unnecessary treatment, avoiding side effects and reducing the cost of treatment (*Li and Brattain, 2006*).

Epidemiology

According to the American Cancer Society, every three minutes a woman in the United States is diagnosed with breast cancer. This cancer incidence in women has increased from one in 20 in 1960 to one in eight nowadays. About 1.3 million women are expected to be diagnosed with this cancer annually worldwide and about 465,000 will die from the disease. Breast cancer death rates have been dropping steadily since 1990 because of earlier detection and better treatment (*Mehmet et al., 2012*).

According to the National Cancer Institute, Cairo, Egypt, breast cancer is the most common cancer among women,

representing 18.9% of total cancer cases. Among the Egypt National Cancer Institute (NCI) series of 10,556 patients during the year 2001 (*Salem et al., 2010*).

There is an international geographical variation in the incidence of Breast Cancer. Incidence rates are higher in the developed countries than in the developing countries. Incidence rates are also higher in urban areas than in the rural areas (*Vorobiof et al., 2001*).

The mortality rates of breast cancer are declining in the developed world (Americas, Australia and Western Europe) as a result of early diagnosis, screening, and improved cancer treatment programs, the converse is true in the developing world (*Adesunkanmi et al., 2006*).

The hallmarks of the disease in Africa are patients presenting at advanced stage, lack of adequate mammography screening programs, preponderance of younger pre-menopausal patients, and a high morbidity and mortality (*Parkin et al., 2005*).